GSK outlines ambitious 10-year plan, but hits investors' near-term outlook

GlaxoSmithKline aims to earn 33 billion pounds, or roughly $46 billion, in annual sales in 2031, betting that new experimental drugs for infectious disease, cancer and immune conditions will drive growth following an exit from consumer healthcare planned for next year.